Nuvalent Receives US FDA Breakthrough Therapy Designation for NVL-520
Nuvalent, a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that the U.S. Food and Drug Administration (FDA)